Cabaletta Bio, Inc. Annual Report - How They Did This Year

Hey there! Thinking about Cabaletta Bio? Wondering what's new? You're in the right spot. We'll explain their latest annual report simply. No confusing financial jargon here. Think of this as a chat with a friend. We'll help you see if this company is doing well. And if it fits your investment goals.

This report covers their performance through December 31, 2025.

Here are quick facts about Cabaletta Bio from their filing:

• Ticker Symbol: CABA (Find them on The Nasdaq Global Select Market)
• Company Size: They are a "smaller reporting company" and "non-accelerated filer." This means they are not a massive corporation. This can suggest higher growth potential. But it also means higher risk. They may have less public reporting than very large companies. For investors, this often means less detailed financial information. Their stock price might also be more volatile. This is due to lower trading volume and market value.
• Market Value (for regular investors): As of June 30, 2025, regular investors owned about $137 million of their common stock. This is called the public float. This number helps you understand how easily you can buy or sell the stock.
• Shares Outstanding: As of March 19, 2026, about 111.3 million common shares existed. This number helps calculate the company's total value. It also helps figure out profit per share, when they have profit.
• Shell Company Status: They are NOT a shell company. This means they actively operate. They have significant business operations. They are not just a corporate entity without real business.

We'll cover your big questions. What do they do? How much money did they make (or lose)? What went well, and what went wrong? What does the future hold?

Here's what we'll look at:

1. What does this company do and how did they perform this year? Cabaletta Bio is a late clinical-stage biotechnology company. This means they find and develop new medicines. But their products are still in human testing. They are not yet approved for sale. So, they don't earn money from product sales. They operate at a loss. They invest heavily in research and development. Their main goal is to create innovative engineered T cell therapies. These therapies help people with autoimmune diseases. Imagine using a patient's own immune cells (T cells). This "resets" their immune system. The goal is deep, lasting, and possibly curative responses. All from just one treatment.

   Their special approach is the CABA® platform. It uses CARTA (Chimeric Antigen Receptor T cells for Autoimmunity). This platform targets and removes disease-causing B cells. B cells are immune cells linked to many autoimmune conditions. They believe this platform could treat dozens of autoimmune diseases. This represents a broad potential market.

   Their lead product is rese-cel (formerly CABA-201). It is currently in human trials. This treatment temporarily removes all B cells. B cells are immune cells that cause autoimmune problems. Then, healthy new B cells grow back. This effectively "resets" the immune system. This year, rese-cel is in Phase 1/2 RESET™ clinical trials. These trials cover systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and generalized myasthenia gravis (gMG). They even started a registrational trial for dermatomyositis (DM) or anti-synthetase syndrome (ASyS). A February 2026 Nature Biotechnology publication reviewed rese-cel's effectiveness and safety. This is a positive sign. It shows scientific interest and validation from the scientific community. Nature Biotechnology has a high impact and reputation.

   How they performed this year (so far): As a clinical-stage company, "performance" isn't about selling products. It's about advancing research and trials. It's also about getting regulatory approvals. And strengthening manufacturing. This year was very active and positive for their clinical development. They made significant progress with rese-cel, their lead candidate, by:

   • Starting a registrational trial for dermatomyositis (DM) or anti-synthetase syndrome (ASyS) in December 2025. A "registrational trial" is a big step. It's usually the final testing stage (often Phase 3). This happens before seeking approval from regulators like the FDA. This move shows strong confidence in earlier data. It also shows a clear path toward potential market approval.
   • Continuing Phase 1/2 trials for SLE, SSc, and gMG. These trials gather initial safety and effectiveness data. This data informs future, larger trials.
   • Exploring a simpler treatment approach. They are evaluating rese-cel without "preconditioning." This is a chemotherapy step. It often depletes immune cells before cell therapies. If successful, this could greatly reduce treatment burden. It could also improve safety. And broaden patient eligibility.
   • Securing regulatory approvals for a new, automated manufacturing platform. This is the Cellares Cell Shuttle™. In January 2026, this could let them produce rese-cel for thousands of patients yearly. It would be more efficient. And potentially lower cost. This addresses a key challenge for cell therapies.

   However, they have lost significant money since starting. They expect to keep losing money for the foreseeable future. This is typical for biotechs at this stage. They invest heavily in research and development. This happens before any products sell. They often need substantial outside funding to keep operating.

2. Financial performance - revenue, profit, growth metrics Currently, Cabaletta Bio earns no money from product sales. As noted, they have lost significant money. They expect to keep losing money. This is because they invest heavily in developing therapies. For investors, the company's value depends on future drug success. It does not depend on current financial performance. They need to raise much more money. This must happen before they finish products or earn sales. This is critical for their continued operation. Their "going concern" warning highlights this.

3. Major wins and challenges this year Wins:

   • Major Clinical Advancement: They started a registrational trial for rese-cel. This covers DM and ASyS in December 2025. This is a huge step toward potential market approval. It signals the therapy showed enough promise in earlier stages. This warranted a pivotal study.
   • Strong Clinical Data: They decided to start the registrational trial for DM/ASyS. This was based on very positive Phase 1/2 data. All patients with enough follow-up exceeded the trial's main goal. They showed major improvements. They did not need other immune-modifying drugs. This strong effectiveness signal reduces risk for the program.
   • Multiple FDA Designations: They received several important FDA designations. These can speed up development and review. They also provide market advantages:
     • Fast Track Designation for rese-cel in DM (Jan 2024), SLE/LN (May 2023), and SSc (Jan 2024). This allows frequent FDA communication. It also makes them eligible for accelerated approval and priority review.
     • Orphan Drug Designation for myositis (Feb 2024) and SSc (March 2024). This offers incentives like tax credits and fee waivers. It also provides 7 years of market exclusivity if approved. This is for diseases affecting under 200,000 people in the U.S.
     • Rare Pediatric Disease Designation for juvenile dermatomyositis (March 2024). If approved, this can lead to a Priority Review Voucher (PRV). This voucher can speed up another product's review. Or, it can be sold to another company for significant value.
     • Regenerative Medicine Advanced Therapy (RMAT) Designation for myositis (May 2025), SLE/LN (Nov 2025), and SSc (Jan 2026). This is for regenerative therapies. They aim to treat, modify, reverse, or cure serious conditions. It offers benefits similar to Fast Track and Breakthrough Therapy. These include intensive FDA guidance and commitment. These designations show rese-cel's potential. It could address serious unmet medical needs.
   • Scalable Manufacturing: They announced INDa approval in January 2026. This allows manufacturing rese-cel using Cellares Cell Shuttle™. This automated platform could produce treatments for thousands of patients yearly. It would cost Cabaletta less upfront. This is crucial for commercial success. It also helps scale production from trials to market supply.
   • Promising Early Data: Early data explored rese-cel without preconditioning. This is a chemotherapy step. In PV patients, it showed similar positive effects. This suggests a simpler, safer treatment option. It could greatly broaden the therapy's use and patient acceptance. Positive early data for MG also showed good tolerability. Patients had significant improvements. This further validates the CARTA approach.
   • Their rese-cel treatment was highlighted in a Nature Biotechnology publication in February 2026. This suggests strong scientific recognition. Leading researchers in the field are interested in their approach.
   • Their CABA® platform and CARTA approach work for many autoimmune diseases. This could be a huge future opportunity. It could lead to many different products from one core technology.

   Challenges:

   • Significant and ongoing losses: They are losing money. They expect to keep losing money. This is typical for a clinical-stage biotech. But it requires continuous outside funding.
   • Urgent need for more funding: This is a big challenge. The company stated doubt about its ability to continue operating. This is a "going concern" warning. They must get more funding beyond current cash. This is needed by the fourth quarter of 2026. Otherwise, they cannot keep operating. If they fail, they might slow down or stop product development. This would severely impact their stock price and future.
   • Reliance on outside manufacturers: They depend on companies like Minaris, Lonza, and Cellares. These companies make their product candidates for trials. Issues with these partners could cause delays. This includes manufacturing delays, quality problems, or capacity limits. Such issues could delay trials and potential market launch.
   • Reliance on licensed technology: A key part of their intellectual property comes from an IASO license agreement. If this agreement ends, or if disputes arise, it would greatly hurt their business. It would also hurt their ability to develop therapies.
   • Clinical trial hurdles: Clinical trials always have risks. They might struggle to enroll enough patients. Unexpected or severe side effects could occur. Results might not match earlier studies. Getting regulatory approval (like from the FDA) is also long and complex. Success is not guaranteed.
   • Competition: They face stiff competition. Other companies develop autoimmune disease treatments. This includes large drug companies with vast resources. Other biotechs develop alternative cell therapies. Or new small molecule/biologic approaches.
   • Inability to attract/retain talent: As a biotech, success relies on top scientists, clinical experts, and management. Losing key people could disrupt research and development. It could also disrupt strategic direction. This impacts their ability to execute plans.
   • No revenue yet: They earn no money from product sales. It will be a long time before they might. This means they constantly spend cash. They depend heavily on outside funding. This often means more shares issued, reducing your ownership percentage.

4. Financial health - cash, debt, liquidity This is a critical area for Cabaletta Bio now. The company issued a "going concern" warning. This means significant doubt exists about their ability to continue. They need more money to operate. They explicitly state they need to raise additional funding. This will extend operations into the fourth quarter of 2026. This is a serious disclosure for investors. It shows a tight cash position. It also shows high dependence on future fundraising. If they don't get this funding, they might cut back. Or they might stop research and development. This could lead to a big drop in stock value. Or even bankruptcy. Investors should closely watch their fundraising.

5. Key risks that could hurt the stock price As an investor, know these important risks:

   • Running out of cash: Their "going concern" warning is the most serious risk. If they cannot raise more money by Q4 2026, operations could be severely impacted. They might even halt business. This could lead to a complete loss of investment.
   • Clinical trial failures: They've had good news. But their business still depends on their products. Rese-cel, especially, must pass all clinical trials. It must also get regulatory approval. If trials fail due to lack of effectiveness, or unsafe profiles, or unexpected side effects, the stock price could drop. Or if they miss regulatory goals, the stock price could drop significantly.
   • Manufacturing problems: They rely on outside companies for manufacturing. This means delays, quality issues, or higher costs could happen. Supply shortages could also occur if partners have problems. This is true even with the new automated platform. These issues could delay trials or market launch.
   • Loss of intellectual property rights: If their IASO license agreement ends, they could lose crucial rights. Or if their patents are challenged and invalidated. This would severely undermine their business model.
   • Intense competition: Other companies develop autoimmune disease treatments. This includes big drug companies with vast resources. Other innovative biotechs also compete. If a competitor launches first, or offers a better product, or has lower costs, it could greatly hurt Cabaletta Bio's future. It could also hurt their market share.
   • Inability to attract/retain talent: As a biotech, success relies on top scientists, clinical experts, and management. Losing key people could disrupt research and development. It could also disrupt strategic direction. This impacts their ability to execute plans.
   • No revenue yet: They earn no money from product sales. It will be a long time before they might. This means they constantly spend cash. They depend heavily on outside funding. This often means more shares issued, reducing your ownership percentage.

6. Competitive positioning Cabaletta Bio operates in a competitive space. Their risk factors acknowledge this: "We face substantial competition." However, rese-cel was reviewed in a Nature Biotechnology publication. It was reviewed alongside other commercial and academic constructs. This suggests their approach is recognized by scientists. It indicates a potentially unique way it works. Their CABA® platform and CARTA approach aim to "reset" the immune system. This happens with a single treatment. If successful, this could offer a unique advantage. It could differentiate them from existing treatments. Many treatments need chronic use or have less impact. The many FDA designations they received for rese-cel also strengthen their position. These include Fast Track, Orphan Drug, and RMAT. These designations cover multiple conditions. They can accelerate development. They provide market advantages like extended exclusivity. They also signal regulatory confidence in the therapy's potential. Strong early clinical data, especially for DM/ASyS, further supports their unique approach. It shows potential to be a best-in-class or first-in-class therapy.

7. Leadership or strategy changes The company's strong scientific foundation is highlighted by co-founders Aimee Payne, M.D., Ph.D. (a leading expert in B cell autoimmune diseases from UPenn). And Michael Milone, M.D., Ph.D. (a renowned CAR T scientist and Kymriah® co-inventor). Kymriah® is an FDA-approved CAR T therapy. They launched Cabaletta in 2017 with Steven Nichtberger, M.D. He is their CEO. He has extensive biotech leadership experience. Their goal was to bring innovative science to patients. Their President, Science and Technology, Gwendolyn Binder, Ph.D., also has a strong cell therapy background. She held leadership roles at Juno Therapeutics. This experienced team suggests a consistent, focused strategy. They use deep expertise in cell therapy and autoimmunity. Their strategy focuses on their CABA® platform. They also advance rese-cel, their lead product, through clinical trials. This is for autoimmune diseases. Now, they have clearer paths to potential approval. They also develop other products using this platform. This shows a long-term product strategy.

8. Future outlook Cabaletta Bio's future outlook depends heavily on clinical trial success. It also depends on their ability to get more funding. This year set the stage for several key milestones:

   • DM/ASyS Approval Path: They expect to submit a Biologics License Application (BLA) in 2027. This is the formal application for market approval. It's for rese-cel in DM/ASyS. This is a major goal. It's a significant catalyst for the company. It represents years of development. It also shows potential for their first commercial product.
   • More Clinical Data: They expect to release complete Phase 1/2 data for SLE, SSc, and gMG programs. This will happen in the first half of 2026. Positive data will be crucial. It will advance these programs to later stages. It will also boost investor confidence.
   • New Registrational Designs: They plan to announce designs for registrational cohorts for SSc. This will be in the first half of 2026. For gMG, it will be in mid-2026. This shows potential paths to approval for these conditions. These announcements will clarify next steps and timelines.
   • Manufacturing Scale-Up: First clinical experience is expected in the first half of 2026. This is from patients treated with rese-cel. It's manufactured using the new Cellares Cell Shuttle™ automated platform. Durability data will follow in the second half of 2026. This is crucial for confirming scalability. It also confirms cost-effectiveness of their manufacturing. This is a key hurdle for cell therapies.
   • No-Preconditioning Approach: They will keep evaluating rese-cel without preconditioning in lupus patients. If successful, this could simplify treatment. It might expand the patient population. It would also improve the therapy's competitive profile.
   • Pediatric Expansion: They plan a pediatric submission for JIIM. This is based on adult data. It could expand their market reach. This would include a vulnerable patient population.
   • Funding is Key: A major part of their future is raising substantial additional funding. This is needed to continue operations. This is especially true given the "going concern" warning. And their cash lasting only until Q4 2026. Successful fundraising is paramount. It will let them achieve these clinical milestones.
   • They believe rese-cel can provide "deep and durable responses." It can also "reset the immune system." This is for many autoimmune diseases. This positions it as a potentially transformative therapy.

9. Market trends or regulatory changes affecting them The company knows government laws and regulations could impact their business. This includes new legislation on drug pricing, manufacturing, or approval pathways. This applies in the US and other countries. They also face a challenge. They must agree with regulators like the FDA. This agreement covers how to assess their products during development. This can be complex for new cell therapies. However, their numerous FDA designations are direct regulatory benefits. These include Fast Track, Orphan Drug, Rare Pediatric Disease, and RMAT. These designations can:

   • Accelerate development and review: They could get therapies to patients faster. This allows more frequent FDA interactions. It also allows expedited review processes.
   • Provide market exclusivity: Orphan Drug and Rare Pediatric Disease designations can grant extra years of market exclusivity if approved. Orphan Drug offers 7 years. Rare Pediatric Disease offers a Priority Review Voucher. This protects their product from generic competition. It also boosts commercial value.
   • Signal regulatory interest: The RMAT designation is for regenerative medicine therapies. These therapies address unmet medical needs. It shows the FDA sees great potential in rese-cel. It also shows commitment to supporting its development. The market trend favors innovative cell and gene therapies. These treat complex diseases. This is good for companies like Cabaletta Bio. Investors and scientists show significant interest in these treatments. However, regulatory paths for these advanced treatments are complex. They are also evolving. This requires careful navigation and substantial resources.